Pfizer Reaches a $486 Million Settlement Regarding Celebrex, Bextra Litigation

September 12, 2017
By: Kathy VanderVeur

In August 2016, Pfizer Inc. reached a $486 million settlement regarding a litigation case accusing Pfizer of causing big losses for shareholders by concealing safety risks associated with its Celebrex and Bextra pain-relieving drugs. This settlement was reached nearly seven years after Pfizer agreed in September 2009 to pay $2.3 billion to settle a U.S. government probe into the marketing of Bextra and other drugs.

Click to Read Article:

View All